compound semaglutide shortage Weight Loss Drug Shortage: Ozempic Impact, Drugs Legality & FDA's Warning Maker of Ozempic and Wegovy

Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al

Wilhite K et al

This raises concerns about unsupervised use and highlights the need for caution until more safety data becomes available (2 Trusted Source Retatrutide-A Game Changer in Obesity Pharmacotherapy Go to source)

If weight regain starts, the doctor may review: Medication dose and adherence

Emerging alternatives and next-generation treatments The GLP-1 space is evolving rapidly

Oral semaglutide (Rybelsus) is the only tablet form currently available